[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL126185A0 - Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs - Google Patents

Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Info

Publication number
IL126185A0
IL126185A0 IL12618597A IL12618597A IL126185A0 IL 126185 A0 IL126185 A0 IL 126185A0 IL 12618597 A IL12618597 A IL 12618597A IL 12618597 A IL12618597 A IL 12618597A IL 126185 A0 IL126185 A0 IL 126185A0
Authority
IL
Israel
Prior art keywords
vitamin
tpgs
compositions
compound
water soluble
Prior art date
Application number
IL12618597A
Other versions
IL126185A (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL126185A0 publication Critical patent/IL126185A0/en
Publication of IL126185A publication Critical patent/IL126185A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12618597A 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor, a water soluble vitamin e compound and a hydrophilic non-aqueous solvent IL126185A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations
PCT/EP1997/001438 WO1997035587A1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Publications (2)

Publication Number Publication Date
IL126185A0 true IL126185A0 (en) 1999-05-09
IL126185A IL126185A (en) 2003-05-29

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12618597A IL126185A (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor, a water soluble vitamin e compound and a hydrophilic non-aqueous solvent

Country Status (12)

Country Link
JP (1) JP3117726B2 (en)
AR (1) AR006345A1 (en)
BG (1) BG64457B1 (en)
CO (1) CO4790151A1 (en)
HU (1) HU228026B1 (en)
ID (1) ID16781A (en)
IL (1) IL126185A (en)
MY (1) MY126358A (en)
OA (1) OA10880A (en)
PL (1) PL187919B1 (en)
TW (1) TW455491B (en)
WO (1) WO1997035587A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (en) * 1997-12-04 2000-10-16 Univ Granada USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
US20040053936A1 (en) * 2000-12-22 2004-03-18 Yohko Akiyama Medicinal composition for oral use
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
CA2578356C (en) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
EP1793806A2 (en) * 2004-09-30 2007-06-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (en) 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
NZ244986A (en) * 1991-11-08 1995-10-26 Merck & Co Inc Hiv protease inhibitor and pharmaceutical compositions
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0674513B1 (en) * 1992-12-29 1996-09-25 Abbott Laboratories Retroviral protease inhibiting compounds
AU6087194A (en) * 1993-01-15 1994-08-15 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
ATE215952T1 (en) * 1993-12-15 2002-04-15 Merck & Co Inc HIV PROTEASE INHIBITORS
EP0749421B1 (en) * 1994-03-07 1999-09-15 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2221145A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
MY126358A (en) 2006-09-29
AR006345A1 (en) 1999-08-25
OA10880A (en) 2001-10-11
BG64457B1 (en) 2005-03-31
TW455491B (en) 2001-09-21
JP2000500504A (en) 2000-01-18
BG102838A (en) 1999-09-30
CO4790151A1 (en) 1999-05-31
HUP9901887A3 (en) 2000-02-28
PL187919B1 (en) 2004-11-30
WO1997035587A1 (en) 1997-10-02
ID16781A (en) 1997-11-13
HUP9901887A2 (en) 1999-12-28
PL328916A1 (en) 1999-03-01
IL126185A (en) 2003-05-29
HU228026B1 (en) 2012-08-28
JP3117726B2 (en) 2000-12-18

Similar Documents

Publication Publication Date Title
IL110752A0 (en) Pharmaceutical composition for an hiv protease inhibitor
HU0900219D0 (en) Hiv protease inhibitor
HUP0002932A3 (en) Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid
HUP0103806A3 (en) Serine protease inhibitor and pharmaceutical compositions containing them
IL109503A0 (en) Hiv protease inhibitors and pharmaceutical compositions containing them
IL126185A0 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
HUP9900456A3 (en) Surfactant compositions
IL120311A0 (en) Serine protease inhibitors and pharmaceutical compositions containing them
HUP0201591A2 (en) Pharmaceutical formulations comprising an hiv protease inhibitor
HUP0002951A3 (en) Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
IL120310A0 (en) Serine protease inhibitors and pharmaceutical compositions containing them
ZA949147B (en) Pyrone derivatives as protease inhibitors and antiviral agents
ZA949148B (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
NZ237733A (en) Neutral metalloprotease inhibitors and pharmaceutical compositions
AU9061798A (en) Protease variants and compositions
GB2284215B (en) Concentrated surfactant compositions
CY2444B1 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs.
HUP0001976A3 (en) Antiviral protease inhibitors and pharmaceutical compositions
NZ237732A (en) Neutral metalloprotease inhibitors and pharmaceutical compositions
GB9323449D0 (en) Concentrated surfactant compositions
AU9061898A (en) Protease variants and compositions
ZA943170B (en) Aqueous based surfactant compositions
GB9714320D0 (en) Hiv protease inhibitor
HK1022441A1 (en) Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid
GB9306198D0 (en) Concentrated surfactant compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired